Hypertension is a major risk factor for cardiovascular disease, which is the leading cause of mortality in women in developed countries. This pooled analysis assessed the antihypertensive efficacy, safety and tolerability of monotherapy with the direct renin inhibitor aliskiren (150 mg and 300 mg) over 8-12 weeks in women with mild-to-moderate hypertension (mean sitting diastolic blood pressure (msDBP)X95 and o110 mm Hg) across eight randomized and double-blind trials. Safety and tolerability were assessed in the five placebo-controlled trials in the analysis. In the 1527 women enrolled in these studies, aliskiren 150 mg and 300 mg produced significantly greater blood pressure (BP) reductions (14.1/11.0 and 16.1/12.3 mm Hg, respectively) compared with placebo (7.2/7.6 mm Hg; Po0.0001). BP reductions with aliskiren monotherapy in women were similar to those observed in men, and consistent across subgroups of age, metabolic syndrome and obesity. The overall incidence of adverse events in women was similar with aliskiren treatment (150 mg, 42.3%; 300 mg, 46.0%) and placebo (39.0%); adverse events with aliskiren were more frequent in women than in men, consistent with previous studies of gender differences in drug tolerability. In conclusion, aliskiren monotherapy at 150 mg and 300 mg doses provided effective, dose-dependent BP-lowering in women with mild-to-moderate hypertension, and it was well tolerated.
Introduction
Although cardiovascular disease (CVD) is often perceived as being a 'male' disease because of its high incidence in middle-aged men, it is the leading cause of mortality and morbidity in women in developed countries. Worldwide, almost half of all deaths from coronary heart disease occur in women 1 and in the United States of America, more women than men die from CVD each year. 2 Despite this, many women remain unaware of the risk posed by CVD. In a 2006 survey, only 57% of women identified heart disease as the leading cause of death among women. 3 Hypertension, diabetes, obesity and hypercholesterolaemia are major risk factors for CVD in both men and women. However, evidence suggests that these factors may make a greater contribution to cardiovascular risk in women than in men. [4] [5] [6] Hypertension is an important risk factor for CVD in women and it is more prevalent in women than men in people aged 55 years and above. 2 Furthermore, there is an age-dependent increased prevalence of hypertension in postmenopausal compared with pre-menopausal women corresponding to a fourfold greater risk of coronary heart disease. 7 Well-controlled clinical trials have shown that effective antihypertensive treatment improves cardiovascular outcomes similarly in women and men, irrespective of age. 8, 9 Moreover, in developed countries, awareness of hypertension is generally higher among women than men, as are treatment rates. However, rates of blood pressure (BP) control remain low; overall, only about one-third of women with hypertension achieve BP control in the United States of America, with lower rates reported in some European countries. [10] [11] [12] Findings from the Women's Health Initiative study suggest that inadequate intensity of antihypertensive therapy could account for these poor BP control rates. 13 Taken together, these findings point to a need for more effective treatment options for women with hypertension. Aliskiren, the first in a new class of oral direct renin inhibitors, is approved for the treatment of hypertension at once-daily doses of 150 mg and 300 mg. In a large clinical trial programme involving approximately 5500 women with hypertension, aliskiren demonstrated effective BP lowering and was generally well tolerated in short-and long-term (up to 52 weeks) studies, both as monotherapy and in combination with other antihypertensive agents. 16 This pooled analysis of eight clinical trials assessed the antihypertensive efficacy, safety and tolerability of aliskiren 150 mg and 300 mg monotherapy in women with mild-tomoderate hypertension.
Patients and methods

Study design
This pooled analysis evaluated efficacy data from eight randomized, double-blind, multicentre studies of aliskiren monotherapy in patients with mildto-moderate hypertension (Table 1). 14,15,17-22 Data were analysed for aliskiren 150 mg and 300 mg (the US Food and Drug Administration and European Union approved doses for the treatment of hypertension) and placebo after 8 or 12 weeks of treatment for the subgroups of women and men. All of the trials were 8 weeks in duration, except for the aliskiren vs ramipril (6 months) and aliskiren vs HCT (12 months) studies. 19, 22 In these two long-term trials, the effects of aliskiren monotherapy were assessed after 12 weeks, before the optional addition of HCT (aliskiren vs ramipril study) or amlodipine (aliskiren vs HCT study) was permitted for BP control. Patients in the aliskiren vs ramipril study started treatment with aliskiren 150 mg, with optional dose titration to 300 mg allowed for BP control after 6 weeks. 19 Patients in the aliskiren vs HCT study underwent forced titration from aliskiren 150 mg to 300 mg after 3 weeks. 22 
Patients
All eight studies enrolled patients X18 years of age with mild-to-moderate hypertension (mean sitting diastolic BP (msDBP) X95 mm Hg and o110 mm Hg). For inclusion in the aliskiren/ramipril study, 21 patients also had to have type I or type II diabetes mellitus. In all of the studies, patients with severe hypertension (msDBPX110 mm Hg and/or mean sitting systolic BP (msSBP) X180 mmHg), a history or evidence of secondary hypertension, or a history of severe cerebrovascular or CVD were excluded. Pregnant or nursing women were also excluded from these studies.
All studies were conducted according to the ethical principles of the Declaration of Helsinki. Study protocols and any amendments were reviewed and approved by the independent ethics committee or institutional review board for each study centre, and patients provided written informed consent before participating in any of the studies.
Assessments
The efficacy of aliskiren 150 mg or 300 mg monotherapy was assessed in eight double-blind, The aliskiren vs ramipril and aliskiren vs HCT studies were long-term trials (6 and 12 months, respectively) with dose titrations. Short-term blood pressure reductions with aliskiren monotherapy at week 12 were assessed for the pooled analysis.
parallel-group, placebo-and/or active-controlled studies ( Table 1) . The pooled efficacy analysis assessed the mean change in msSBP and msDBP from baseline, and BP control (msSBP/DBP o140/ 90 mm Hg) and responder rates (msDBP o90 mm Hg and/or X10 mm Hg reduction from baseline), at the end of the monotherapy treatment period (week 8 for six studies and week 12 for two studies; Table 1 ). The safety and tolerability of aliskiren monotherapy was assessed in the five double-blind, parallelgroup, placebo-controlled studies (Table 1) . Adverse events were recorded at each study visit and assessed by study investigators for severity and likely relationship to study medication. Standard laboratory analyses were carried out during each study and the proportions of patients meeting pre-defined laboratory safety parameters (serum potassium concentrations o3.5, 45.5 and X6.0 mmol l À1 , serum creatinine 4176.8 mmol l À1 and blood urea nitrogen levels 414.28 mmol l À1 ) were recorded.
Statistical analysis
Data from the male and female subgroups were analysed separately. Changes in msSBP from baseline to study endpoint were analysed using an analysis of covariance model with treatment as a factor and baseline msSBP as a covariate. A similar analysis was carried out for change in msDBP from baseline to endpoint. Responder and BP control rates at study endpoint were analysed using a logistic regression model with treatment as a factor and baseline msDBP as a covariate. Endpoint was defined as the last postrandomization measurement collected during the monotherapy treatment period (week 8 for six studies and week 12 for two studies; Table 1 ). Further analyses were carried out for the following subgroups of female patients (which were defined using data collected at baseline): non-elderly (o65 years) or elderly (X65 years); pre-menopausal (o50 years), menopausal (50-55 years inclusive) or postmenopausal (455 years); non-obese (body mass index o30 kg m À2 ) or obese (body mass index X30 kg m À2 ); without metabolic syndrome or with metabolic syndrome (defined according to NCEP ATP III criteria 23 ). For each subgroup the changes from baseline in msSBP and msDBP and the BP control rates were analysed as described above.
Results
Patient demographics
The pooled analysis involved a total of 3591 patients with hypertension. In all, 1527 women were included (42.5%), and the proportion of women was similar across the three treatment groups analysed (aliskiren 150 mg, 41.6%; aliskiren 300 mg, 44.1%; and placebo, 40.7%). Within the gender subgroups, patient demographics were generally similar across the three treatment groups (Table 2 ). Women participating in the studies tended to be slightly older than men (range of means 55.1-57.3 years vs 52.9-55.3 years), with a longer duration of hypertension (7.8-8.2 years vs 6.5-7.8 years). Few patients in this analysis discontinued aliskiren treatment and the incidence was similar in women (150 mg, 7.3%; 300 mg, 5.8%) and men (150 mg, 6.8%; 300 mg, 6.6%). Discontinuation rates with placebo were higher than with aliskiren therapy for both women (12.5%) and men (12.9%), primarily because of the higher numbers of discontinuations due to unsatisfactory therapeutic effect with placebo (5.0-5.6%) than with active therapy (1.5-2.3%). The reasons for discontinuation from aliskiren treatment were similar across doses and genders, with adverse events (0.8-2.7%) and withdrawal of consent (0.9-2.3%) being the most commonly reported reasons.
Efficacy
Aliskiren 150 mg and 300 mg provided significantly greater, dose-dependent reductions from baseline in msSBP and msDBP compared with placebo in women with hypertension (all Po0.0001; Figure 1 ). Mean BP reductions at endpoint with both aliskiren doses were slightly larger in women than in men, although the placebo-adjusted changes were similar in women and men for the 150 mg and 300 mg doses.
Blood pressure control rates in women were significantly higher with aliskiren 150 mg (42.3%) and 300 mg (46.4%) monotherapy than with placebo (26.7%; both Po0.0001) (Figure 2 ). Control rates with aliskiren treatment were higher in women than in men, although placebo-adjusted rates were similar in both genders. In women, responder rates were also significantly higher with aliskiren 150 mg (62.6%) or 300 mg (72.5%) than with placebo (47.6%; both Po0.0001); similar responder rates were observed in men (150 mg, 56.3%; 300 mg, 67.3%; placebo, 35.6%; Po0.0001).
Subgroup analyses in women showed that BP reductions with aliskiren monotherapy were similar in elderly and younger patients, in patients with and without metabolic syndrome and in obese and nonobese patients (Table 3) . Although reductions from baseline in msSBP with aliskiren 300 mg tended to be larger in the subgroups of elderly women and those without metabolic syndrome or obesity, there were no notable differences for placebo-corrected BP changes. In all of these subgroups, BP reductions from baseline with aliskiren 150 mg and 300 mg were significantly greater than with placebo (all Pp0.0009).
Subgroup analysis by age (o50, 50-55 and 455 years) was used to assess the effects of menopausal status on the response to aliskiren monotherapy. Baseline msSBP increased with increasing Aliskiren in women with hypertension AH Gradman et al age; reductions in BP with aliskiren 150 mg or 300 mg were generally similar across age groups ( Figure 3 ). In addition, the effect of oestrogen therapy was assessed by subgroup analysis in the five placebo-controlled studies, although only small numbers of women received oestrogen in these trials (150 mg, n ¼ 35 (out of 298); 300 mg, n ¼ 27 (out of 326)). There was no consistent effect of oestrogen therapy on the BP-lowering efficacy of aliskiren 150 mg or 300 mg (data not shown).
Safety and tolerability
Aliskiren 150 mg and 300 mg showed a similar tolerability profile to placebo in women with hypertension. The overall incidence of adverse events in women was similar in both aliskiren groups (150 mg, 42.3%; 300 mg, 46.0%) and in the placebo group (39.0%). The majority of adverse events were transient and either mild or moderate in intensity and few women discontinued because of adverse events (2.0-2.8%). The most frequently reported adverse events in all the three treatment groups were headache and nasopharyngitis. The overall incidence of adverse events in both the aliskiren 150 mg and 300 mg groups was higher in women than in men (Table 4) . However, the most frequently reported adverse events were the same for both genders, and there were no notable differences in either the type of adverse events or their frequency that would account for the overall difference in incidence seen between the genders. Some small differences in incidence were observed between genders. Headache was reported less frequently with aliskiren 150 mg and 300 mg therapy than with placebo by both women and men, although the difference was more marked in men. Diarrhoea showed a larger difference in incidence between aliskiren 300 mg and placebo in women (3.0 vs 1.3%) than in men (1.8 vs 1.1%), but rates Aliskiren in women with hypertension AH Gradman et al remained low. The incidence of cough was low (o2%) in both women and men in all three treatment groups; the incidence was similar in women and men with aliskiren 150 mg, although cough was more frequent in women than in men at the 300 mg dose. The incidence of abnormal laboratory values during the study was low and similar in women and men (Table 4) . Serum potassium levels o3.5 mmol l À1 were more frequent with placebo in both women (3.9%) and men (2.9%) than with aliskiren therapy (1.0-1.4%). Serum potassium elevations 45.5 mmol l À1 occurred infrequently across genders and treatment groups (0.5-1.4%), and only three patients (two male and one female) exhibited serum potassium levels X6.0 mmol l À1 .
Discussion
Our pooled analysis shows that once-daily treatment with aliskiren monotherapy at doses of 150 mg and 300 mg provides effective, dose-dependent BP-lowering in women with mild-to-moderate hypertension, similar to the effects observed in men. The antihypertensive effects of aliskiren monotherapy in women were consistent across subgroups of age, metabolic syndrome and obesity. Both doses of aliskiren showed a similar tolerability profile to placebo in women and men. Aliskiren 150 mg and 300 mg produced significantly greater reductions in BP than placebo in women after 8-12 weeks' treatment. BP control rates and responder rates were also significantly greater with aliskiren treatment than placebo. Subgroup analyses in women showed that aliskiren therapy provided effective BP lowering in elderly patients (X65 years), obese patients and those with metabolic syndrome. The decreases in BP seen with aliskiren therapy in elderly women were similar to those seen in younger individuals. Effective antihypertensive treatment in older women is important in reducing the burden of hypertension, as the prevalence of hypertension in the elderly is higher in women than men, 2 and the proportion of women achieving BP control decreases with age. 11, 12 The subgroup analysis also showed that aliskiren monotherapy was effective in hypertensive women with metabolic syndrome and those with obesity. Previous studies of aliskiren in both men and women with hypertension have shown similar BP reductions in patients with and without metabolic syndrome, 24 and in obese and non-obese patients. 25 Metabolic risk factors for cardiovascular morbidity and mortality, particularly obesity, are common in women with hypertension. In a recent survey of patients with diagnosed hypertension, central obesity was significantly more prevalent in women than men (79 vs 64%), as were elevated total cholesterol (61 vs 48%) and low HDL cholesterol (40 vs 36%). 26 Furthermore, significantly more women than men had three or more cardiovascular risk factors (53 vs 
Laboratory abnormalities
Abbreviations: AE, adverse event; BUN, blood urea nitrogen; URTI, upper respiratory tract infection.
Aliskiren in women with hypertension AH Gradman et al 41%), underlining the importance of effective BP control in women with hypertension and metabolic disorders. Subgroup analysis by age (used as a surrogate for menopausal status) suggested that menopausal status had little effect on the BP-lowering efficacy of aliskiren, Although there is a clear age-dependent increase in the prevalence of hypertension in women, 2 the relationship between menopausal status and hypertension is uncertain; some studies report an increase in BP related to menopause, whereas others suggest that factors such as age, weight and physical activity can account for this apparent relationship. 27, 28 The findings from this analysis suggest that aliskiren provides effective BP reductions in women, irrespective of menopausal status. The effects of oestrogen use on aliskiren therapy were unclear, probably reflecting the small numbers of women receiving oestrogen in these clinical trials. Studies examining the effects of hormone-replacement therapy on antihypertensive treatments are limited, although an observational study in postmenopausal women with hypertension showed that the antihypertensive efficacy of candesartan (alone or in combination with HCT) was similar with or without hormone replacement therapy. 29 The antihypertensive efficacy of aliskiren in women was similar to that observed in men. This is consistent with findings with other antihypertensive agents, although analyses examining effects of antihypertensive medications by gender in hypertension are limited. 30 Some studies have reported differences between genders. In the HANE (hydrochlorothiazide, atenolol, nitrendipine and enalapril) study in patients with mild-to-moderate hypertension, the overall response rate (DBPo90 mm Hg) was higher in women (55%) than men (48%), and enalapril provided significantly higher response rates in women than in men. 31 In this pooled analysis, both the 150 mg and 300 mg doses of aliskiren were generally well tolerated in women. The type, severity and overall incidence of adverse events reported for aliskiren 150 mg and 300 mg were similar to those observed with placebo, and there were no clear differences in the types of adverse events between genders. Adverse events on aliskiren treatment were more frequently reported in women than in men. This is consistent with the previous studies that suggest that women tend to experience more adverse events with drug treatment than men. 32, 33 The underlying reasons are not fully understood, although gender-related differences in pharmacokinetics and pharmacodynamics, hormonal factors and medication use may all play a role. 34, 35 Differences in the incidence of adverse events between genders have been observed in some studies in patients with hypertension. In the TOMHS (Treatment Of Mild Hypertension Study), adverse events were reported more frequently by women than men, although the incidence was similar in the treatment and placebo groups. 36 Gender-based differences in tolerability have been observed with some antihypertensive treatments, although the reasons for these differences have yet to be elucidated. ACE-inhibitor-induced cough and lower extremity oedema with calcium-channel blockers have been reported more frequently in women than in men. [37] [38] [39] [40] [41] In this analysis, the incidence of cough with aliskiren monotherapy was low (o2%) in both women and men; the incidence of peripheral oedema in women in the aliskiren groups was also low (0.9-1.0%) and similar to that observed in men (0.6-0.9%).
Changes in biochemical parameters with antihypertensive medication may also show differences between genders. Both hyponatraemia and hypokalaemia associated with diuretic therapy are more frequent in women than in men. [42] [43] [44] [45] In the current study, the incidence of serum potassium levels o3.5 mmol l À1 with aliskiren therapy was low (1.0-1.4%) and did not differ between genders. Similarly, few women or men experienced serum potassium elevations 45.5 mmol l À1 with aliskiren therapy (0.7-1.4%).
In conclusion, aliskiren monotherapy at doses of 150 mg and 300 mg provided effective, dose-dependent BP-lowering in women with mild-to-moderate hypertension, and was generally well tolerated. Aliskiren treatment showed similar antihypertensive efficacy and tolerability in both women and men. Furthermore, aliskiren treatment demonstrated effective BP lowering in women who were elderly, obese or had metabolic syndrome. These results suggest that aliskiren offers an effective and welltolerated option for the treatment of hypertension in women.
What is known about this topic K Cardiovascular disease is often perceived as being a 'male' disease because of its high incidence in middle-aged men, but it is also the leading cause of mortality and morbidity in women in developed countries. K Effective blood pressure (BP) control is important to reduce the risk of cardiovascular disease in men and women, but relatively few studies have specifically evaluated the BPlowering effects of antihypertensive therapy in women. K The direct renin inhibitor (DRI) aliskiren is approved for the treatment of hypertension at once-daily doses of 150 mg and 300 mg, and has been shown to provide highly effective BP reduction with good tolerability across a broad range of patients with hypertension.
What this study adds K Aliskiren 150 and 300 mg monotherapy provided effective BP reductions in women similar to those observed in men, and these were consistent across subgroups of age (menopausal status), metabolic syndrome and obesity. K The overall incidence of adverse events in women was similar with aliskiren treatment (150 mg, 42.3% and 300 mg, 46.0%) and placebo (39.0%), and there were no notable differences between genders. K Aliskiren therefore provides an effective and well-tolerated option for the treatment of hypertension in women.
